Towards personalized medicine for refractory/relapsed Follicular Lymphoma patients: the Cantera/Lupiae registry
Recruiting
- Conditions
- follicular lymphoma
- Registration Number
- NL-OMON28193
- Lead Sponsor
- EHA Lymphoma group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
Patients with initial diagnosis of follicular lymphoma, refractory/relapsed/transformed after first line therapy, All stages at the time of relapse, Histological grade 1-3a at the time of initial diagnosis, Age over 18 years, Availability of clinical data, including baseline information, comorbidities, data on disease localization, laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating as requested, Diagnostic material available for review, Written informed consent.
Exclusion Criteria
Age < 18 years
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of Progression of disease within 24 months from start of second line treatment (second POD24)
- Secondary Outcome Measures
Name Time Method Overall Survival (OS), Progression-free survival after second line therapy (second PFS), Complete response rate at 30 months (CR30) from start of second line treatment (second CR30)